Furthermore, ANA-12 has been used to target NTRK2 in studies of medulloblastoma (Thomaz et al., 2019), gliomas (Pinheiro et al., 2017), leukemia (Polakowski et al., 2014), lung adenocarcinoma metastasis (Sinkevicius et al., 2014), lymphoid tissue neovascularization (Dalton et al., 2015) and endometriosis (Lee et al., 2021), etc. Experimental validation was performed on the hub gene. This evidence concerns the gene NTRK2 and leukemia.